the virus, according to the companies. This double-blind trial of 400 participants will begin at 16 medical centers in New York.
“This work is critical to national efforts to respond to the threat of this emerging virus,” Dr. Lisa Jackson, senior investigator at Kaiser Permanente Washington Health Research Institute said. “We are prepared to conduct this important trial because of our experience as an NIH clinical trials center since 2007.”
Adults in the Seattle area who are interested in joining this study should visit https://corona.kpwashingtonresearch.org. For more information about the study, visit ClinicalTrials.gov and search identifier NCT04283461.